HealthcareRequest a quote CDMO partnership overview
One accountable partner for your pharmaceutical portfolio. Walter coordinates product feasibility, manufacturing, development, transfer and packaging, with facility scope and market requirements reviewed for each project.
Network capacity desk
For early commercial conversations, Walter models all six units on the Unit III production baseline, operating two 8-hour shifts across 300 operating days. This creates one clear network view before the product, site and campaign plan are fixed.
Planning model · not a manufacturing commitment17.28m per two-shift day across six parallel lines.
120–144K bottles per two-shift day.
96–120K tubes per two-shift day.
Up to 864K blister or strip packs per two-shift day.
Combined batch capability
Combined network equipment & infrastructure
Combined utility platform
Planning context: These figures are intended to frame early portfolio conversations. Final manufacturing scope, campaign capacity, facility allocation, equipment availability and regulatory permissions are confirmed jointly during technical feasibility and quality review.
Product and process fit
The CDMO overview is designed for portfolio and relationship decisions. Use the dedicated capabilities page to review dosage forms, process steps, representative line throughput and the technical context needed for your product brief.
For an oral-solid brief, review tablet manufacturing or capsule manufacturing. Include the composition, strength, release or coating requirements, pack, quantity and intended market.
Explore dosage forms & process capabilitiesTechnical detail
Focused pages keep technical profiles and protected presentations available without interrupting the CDMO overview.
GMPExplore Walter’s manufacturing controls, infrastructure and the protected PlantSure™ technical brochure.
Open focused page
SVPReview the dedicated Unit IV sterile manufacturing scope and injectables profile.
Open focused page
22Take a representative, protected 22-page visual tour of Walter Healthcare Unit III.
Open focused page
LABReview Walter’s GLP-focused laboratory infrastructure, analytical workflow and protected LabTrust™ brochure.
Open focused pageWays to work with Walter
Move selected products or a wider portfolio into a more consolidated manufacturing relationship.
Translate an approved composition or development brief into a commercially manufacturable product.
Add qualified external capacity without building and operating another manufacturing block.
Reduce coordination across multiple vendors by bringing varied dosage forms into one network.
Third-party pharma manufacturing in India
For a specific product, use the focused manufacturing guides to prepare the formula, release type, pack, quantity and market brief. For a wider portfolio, Walter coordinates the feasibility review across the relevant capabilities.
The manufacturing journey
Explore the five controlled stages that turn a product requirement into a coordinated manufacturing, quality and dispatch programme.
Each project remains subject to technical feasibility, relevant manufacturing permissions, commercial alignment and applicable regulatory requirements.
Buyer questions
Send the exact composition, strength, dosage form, release type, target market, initial quantity and pack configuration. State whether this is a new launch, development project or technology transfer. Separate the first order from the annual forecast and identify any required supplier audit or documentation review.
A manufacturing-only brief may start with an established formula, methods and approved packaging. A CDMO engagement may also include agreed development or transfer activities. Walter defines the actual scope, deliverables and responsibilities for your project in the technical and commercial review.
Ask for the Master Formula Record, Batch Manufacturing Record, Batch Packing Record and Method of Analysis, together with specifications, COA and relevant stability or validation information. QA must confirm which documents apply, exist and can be shared. Proprietary or executed records may require an NDA, redaction or controlled review; public catalogue listings do not guarantee a complete dossier.
The catalogue does not set a universal MOQ or delivery commitment. Batch size, material availability, printed-packaging minimums, development or transfer work, testing and release requirements vary by product. Request a written quotation that states quantities, prerequisites and the point at which the lead-time clock starts.
This route is for manufacturing, development and supply feasibility. If you are seeking a franchise, distribution territory or brand rights, state that separately in the enquiry; do not assume monopoly rights or a franchise agreement are included.
Prepare your project
Start the conversation
Share the product list, dosage forms, quantities and target market. We’ll assess the right relationship, manufacturing path and next technical review.
Request a quote